Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1984 2
1985 1
1987 1
1988 1
1989 1
1990 1
1991 1
1992 1
1993 1
1994 2
1995 2
1996 2
1997 5
1998 4
1999 2
2000 5
2001 6
2002 4
2003 3
2004 1
2005 2
2006 3
2007 4
2008 6
2009 3
2010 4
2011 5
2012 4
2013 4
2014 4
2015 8
2016 5
2017 11
2018 10
2019 6
2020 6
2021 9
2022 7
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Immunogenicity Associated with Botulinum Toxin Treatment.
Bellows S, Jankovic J. Bellows S, et al. Toxins (Basel). 2019 Aug 26;11(9):491. doi: 10.3390/toxins11090491. Toxins (Basel). 2019. PMID: 31454941 Free PMC article. Review.
Botulinum toxin (BoNT) has been used for the treatment of a variety of neurologic, medical and cosmetic conditions. ...Other factors contributing to the immunogenicity of BoNT include properties of each serotype, such as formulation, manufacturing, and storage of th …
Botulinum toxin (BoNT) has been used for the treatment of a variety of neurologic, medical and cosmetic conditions. ...Other f …
Antiseizure Drugs and Movement Disorders.
Sáenz-Farret M, Tijssen MAJ, Eliashiv D, Fisher RS, Sethi K, Fasano A. Sáenz-Farret M, et al. CNS Drugs. 2022 Aug;36(8):859-876. doi: 10.1007/s40263-022-00937-x. Epub 2022 Jul 21. CNS Drugs. 2022. PMID: 35861924 Review.
However, antiseizure drugs also represent a potential cause of iatrogenic movement disorders, with parkinsonism and tremor the most common disorders. ...Finally, these notions can lead to a better understanding of the mechanisms involved in the pathophysiolog …
However, antiseizure drugs also represent a potential cause of iatrogenic movement disorders, with parkinsonism and tremor the …
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.
Mahapatra MK, Karuppasamy M, Sahoo BM. Mahapatra MK, et al. Pharm Res. 2022 Jun;39(6):1233-1248. doi: 10.1007/s11095-022-03302-1. Epub 2022 Jun 1. Pharm Res. 2022. PMID: 35650449 Free PMC article. Review.
Various pre-clinical and phase-2 studies have indicated the therapeutic potential of semaglutide in non-alcoholic steatohepatitis and neurodegenerative disorders like Parkinson's and Alzheimer's disease. DISCUSSION: Significant weight reduction ability …
Various pre-clinical and phase-2 studies have indicated the therapeutic potential of semaglutide in non-alcoholic steatohepatitis and neurod …
Oropharyngeal dysphagia in older persons - from pathophysiology to adequate intervention: a review and summary of an international expert meeting.
Wirth R, Dziewas R, Beck AM, Clavé P, Hamdy S, Heppner HJ, Langmore S, Leischker AH, Martino R, Pluschinski P, Rösler A, Shaker R, Warnecke T, Sieber CC, Volkert D. Wirth R, et al. Clin Interv Aging. 2016 Feb 23;11:189-208. doi: 10.2147/CIA.S97481. eCollection 2016. Clin Interv Aging. 2016. PMID: 26966356 Free PMC article. Review.
In addition to swallowing training and nutritional interventions, newer rehabilitation approaches of stimulation techniques are showing promise and may significantly impact future treatment strategies....
In addition to swallowing training and nutritional interventions, newer rehabilitation approaches of stimulation techniques are showi …
Newer medical treatment in parkinsonism.
Schwarz GA, Fahn S. Schwarz GA, et al. Med Clin North Am. 1970 May;54(3):773-85. Med Clin North Am. 1970. PMID: 5423145 No abstract available.
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. Seppi K, et al. Mov Disord. 2011 Oct;26 Suppl 3(0 3):S42-80. doi: 10.1002/mds.23884. Mov Disord. 2011. PMID: 22021174 Free PMC article. Review.
The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on moto …
The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's …
Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome.
Bicknell B, Liebert A, Borody T, Herkes G, McLachlan C, Kiat H. Bicknell B, et al. Int J Mol Sci. 2023 May 31;24(11):9577. doi: 10.3390/ijms24119577. Int J Mol Sci. 2023. PMID: 37298527 Free PMC article. Review.
This link suggests not only that the gut microbiota composition can be used to make an early diagnosis of neurodegenerative and neurodevelopmental diseases but also that modifying the gut microbiome to influence the microbiome-gut-brain axis might present a therapeutic target for …
This link suggests not only that the gut microbiota composition can be used to make an early diagnosis of neurodegenerative and neurodevelop …
General Anesthesia vs Local Anesthesia in Microelectrode Recording-Guided Deep-Brain Stimulation for Parkinson Disease: The GALAXY Randomized Clinical Trial.
Holewijn RA, Verbaan D, van den Munckhof PM, Bot M, Geurtsen GJ, Dijk JM, Odekerken VJ, Beudel M, de Bie RMA, Schuurman PR. Holewijn RA, et al. JAMA Neurol. 2021 Oct 1;78(10):1212-1219. doi: 10.1001/jamaneurol.2021.2979. JAMA Neurol. 2021. PMID: 34491267 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This study was a single-center prospective randomized open-label blinded end point clinical trial. A total of 187 persons with Parkinson disease were referred for DBS between May 2015 to March 2019. ...MAIN OUTCOMES AND MEASURES: T …
DESIGN, SETTING, AND PARTICIPANTS: This study was a single-center prospective randomized open-label blinded end point clinical trial. A tota …
Orphan G protein-coupled receptors: The role in CNS disorders.
Alavi MS, Shamsizadeh A, Azhdari-Zarmehri H, Roohbakhsh A. Alavi MS, et al. Biomed Pharmacother. 2018 Feb;98:222-232. doi: 10.1016/j.biopha.2017.12.056. Epub 2017 Dec 27. Biomed Pharmacother. 2018. PMID: 29268243 Review.
G protein-coupled receptors (GPCRs) have the highest expression with a wide range of physiological functions. A newer sub group of these receptors namely orphan GPCRs have been discovered. ...After a brief presentation of each receptor, considering the results from genetic …
G protein-coupled receptors (GPCRs) have the highest expression with a wide range of physiological functions. A newer sub group of th …
Neurosurgical Approaches to Levodopa-Induced Dyskinesia.
Martini ML, Mocco J, Panov F. Martini ML, et al. World Neurosurg. 2019 Jun;126:376-382. doi: 10.1016/j.wneu.2019.03.056. Epub 2019 Mar 14. World Neurosurg. 2019. PMID: 30880213 Review.
Levodopa has long been the standard of care for Parkinson disease (PD); however, the eventual onset of motor fluctuations and levodopa-induced dyskinesia (LID) complicates its utility in advanced PD. ...Deep brain stimulation (DBS) is currently the procedure of choi …
Levodopa has long been the standard of care for Parkinson disease (PD); however, the eventual onset of motor fluctuations and …
145 results